Diosmin/Hesperidin to Protect Kidneys in Platinum Chemotherapy
Official title: Evaluation of the Effect of Diosmin/Hesperidin Combination on Platinum Compounds-Induced Nephropathy in Cancer Patients: A Randomized Controlled Trial
Run by Beni-Suef University · NCT07598214 · Data updated 2026-11-12
This study tests whether taking diosmin and hesperidin helps protect the kidneys of cancer patients who are receiving platinum-based chemotherapy.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Beni-Suef University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Banī Suwayf) |
| Status | Recruiting |
| Started | February 3, 2025 |
| Main results expected | November 3, 2026 |
| Study ends | December 3, 2026 |
| Registry record updated | May 20, 2026 |
| Trial ID | NCT07598214 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18-75 with cancer undergoing platinum-based chemotherapy and normal to mildly reduced kidney function, willing to take the additional supplement.
✕Probably not a fit
Patients with severe renal impairment (creatinine clearance <50 mL/min), pregnancy, life expectancy under 6 months, or those intolerant to the study drugs may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This prospective randomized controlled trial will enroll about 100 cancer patients undergoing platinum chemotherapy to see if adding a diosmin/hesperidin combination reduces nephrotoxicity. Participants are divided into a control group receiving standard platinum therapy and a test group receiving the same therapy plus 450 mg diosmin and 50 mg hesperidin twice daily. The study runs from January 2025 to September 2025 and will monitor kidney function and safety outcomes. The lead sponsor is Beni-Suef University, with the study conducted at the Faculty of Medicine in Banī Suwayf.
Why it matters
Potential benefit: If successful, patients may experience less kidney damage from platinum chemotherapy.
How similar studies have gone: Previous research has explored protective supplements against chemotherapy nephrotoxicity, with mixed but promising results for similar flavonoid combinations.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients of 18 to 75 year-age must have histologically or cytologically confirmed cancer by the Laboratory of Pathology receiving a platinum compound chemotherapy. Exclusion Criteria: * -History of allergic reactions attributed to drugs in the study. * Pregnant women. * Life expectancy less than 6 months * Inability or unwillingness to comply with research protocols. * Cancer patients with impaired renal function (creatinine clearance \< 50 mL/min) * Preexisting hearing loss. * Patients taking nephrotoxic drugs; and those who have a history of allergic reactions to platinum-containing compounds.
Where it's running
-
Faculty of Medicine
Banī Suwayf, Egypt Recruiting
Study contacts
- Principal investigator: marwa mohsen — clinical pharmacy department, Beni Suef University
- Study coordinator: marwa mohsen, PhD
- Email: marwa.mohsen@pharm.bsu.edu.eg
- Phone: 01202203223
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Tibetree topical herbal plasters for people using opioids for cancer pain
This trial will try Tibetree topical herbal plasters together with prescribed opioids to see if they reduce localized cancer-related pain for adults who are currently taking short-term oral opioids.
-
Comparing two methods of pain control after kidney surgery in cancer patients
This study is testing two different ways to control pain after kidney surgery in cancer patients to see which method works better.
-
Observing liver injury caused by immune checkpoint inhibitors in cancer patients
This study looks at how certain cancer treatments affect the liver in patients to better understand the types of liver injuries and improve their care.
-
Comprehensive mobile app to support diet, nutrition, and activity for people with cancer
This project will test whether a smartphone app called RestoreMe can help people receiving curative-intent radiation for certain cancers use healthier diet, nutrition, and activity habits during treatment.
-
Anxiety treatment for Latino older adults with cancer and their caregivers
This study tests a new anxiety treatment program for Latino older adults with cancer and their caregivers to see if it helps them feel less anxious.
-
Writing exercises for young cancer patients
This study tests if writing about their cancer experiences can help young patients aged 15-25 feel better and improve their well-being.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.